OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.

from http://oncogenex.com/

Patents 33show all

  • 25
    A61K - Preparations for medical, dental, or toilet purposes
  • 18
    C12N - Microorganisms or enzymes
  • 3
    A61N - Electrotherapy
  • 2
    Y02P - Climate change mitigation technologies in the production or processing of goods
  • 1
    A01K - Animal husbandry
  • 1
    C07H - Sugars
  • 1
    G16H - Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data

Clinical Trials 21show all

8Phase 37Phase 24N/A2Other

SEC Filings show all


198
8-K

70
10-Q

24
10-K

2
D

1
S-1

Contact Information

Bothell, WA
United States

SEC Form D Funding Events

DateOfferedSoldType
2010-01-04$10,000,000$10,000,000Equity
2005-11-02Unknown Unknown Other (Paper Filing)

Key Executives

  • Scott Cormack
    Director, Executive Officer
  • Neil James Clendeninn
    Director
  • Michael A. Martino
    Director
  • Michelle Burris
    Director
  • Dwight Winstead
    Director
  • Stephen Anderson
    Executive Officer
  • Cindy Jacobs
    Executive Officer